Trial Profile
Phase 1-2a dose-ranging study of TLK286 [canfosfamide] in combination with paraplatin (carboplatin) in recurrent ovarian cancer.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 28 Jul 2011
Price :
$35
*
At a glance
- Drugs Canfosfamide (Primary) ; Carboplatin (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- 22 Jul 2011 Actual end date (Jan 2005) added as reported by ClinicalTrials.gov.
- 30 Sep 2005 New trial record.